NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NASDAQ:BSX). Investors who purchased Boston Scientific securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/bsx.
The investigation concerns whether Boston Scientific and certain of its officers and/or directors have violated federal securities laws.
On November 17, 2020, Boston Scientific announced a global recall of all unused inventory of the Company's LOTUS Edge Aortic Valve System, citing "complexities associated with the product delivery system." Boston Scientific further announced that "[g]iven the additional time and investment required to develop and reintroduce an enhanced delivery system, the company has chosen to retire the entire LOTUS product platform immediately." On this news, Boston Scientific's stock price fell $3.00 per share, or 7.89%, to close at $35.03 per share on November 17, 2020.
If you are aware of any facts relating to this investigation, or purchased Boston Scientific shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/bsx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC